

CORRECTION

Open Access



Correction: Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer

Jie Mei¹, Leiyu Hao², Xiaorui Liu³, Guangshun Sun⁴, Rui Xu², Huiyu Wang^{1*} and Chaoying Liu^{1*}

Correction: *Biomark Res* 7, 16 (2019)

<https://doi.org/10.1186/s40364-019-0168-9>

The original article [1] contains the following errors:

- 1) The ordinate scale is displayed incorrectly in Fig. 2D-F.
- 2) Fig. 3E was duplicated over Fig. 3F.
- 3) Table 3 contained data in the 'HR', '95% CI', and 'P-value' columns of the 'Adjuvant chemotherapy' and 'Non-chemotherapy' rows that should have been deleted.

The corrected Fig. 2, Fig. 3, and Table 3 all appear ahead. The authors apologize for this error and state that this does not change the scientific conclusion in any way.

Published online: 09 November 2023

The original article can be found online at <https://doi.org/10.1186/s40364-019-0168-9>.

*Correspondence:

Huiyu Wang
wanghuiyu2011@126.com

Chaoying Liu
chylu666@163.com

¹ Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, China

² Department of Physiology, Nanjing Medical University, Nanjing 211166, China

³ School of Pediatrics, Nanjing Medical University, Nanjing 211166, China

⁴ Department of General Surgery, Wuxi People's Hospital Affiliated to, Nanjing Medical University, Wuxi 214023, China

Reference

1. Mei J, Hao L, Liu X, et al. Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer. *Biomark Res.* 2019;7:16. <https://doi.org/10.1186/s40364-019-0168-9>.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 2 Transcriptional levels of PRDXs in various BrCa subclasses. The transcriptional level of PRDXs in BrCa patients with different subclasses, PRDXs mRNA was significantly downregulated (PRDX3) or upregulated (other PRDXs) in HER2-positive and triple-negative BrCa tissues compared with luminal BrCa tissues. **a** PRDX1. **b** PRDX2. **c** PRDX3. **d** PRDX4. **e** PRDX5. **f** PRDX6




Fig. 3 Correlation between the genetic alterations of PRDXs and mRNA levels in BrCa tissues. **a** Oncoprint in cBioPortal database exhibited the proportion and distribution of specimens with genetic alterations in PRDXs. The Figure was cropped on the right to exclude specimens without any alterations. **b-g** Copy gain (gain and amplification) of PRDXs was associated with notably upregulated PRDXs mRNA levels compared with the copy-neutral (diploid) and copy-loss (shallow deletion and deep deletion) cases. **b** PRDX1. **c** PRDX2. **d** PRDX3. **e** PRDX4. **f** PRDX5. **g** PRDX6

Table 3 Association between prognostic value of PRDXs mRNA expression and various chemotherapies in BrCa

Chemotherapies	Cases	HR OS	95%CI	P value	Cases RFS	HR	95%CI	P value
PRDX1								
Adjuvant chemotherapy	163	1.85	1.01–3.40	0.044	594	1.05	0.78–1.42	0.734
Neoadjuvant chemotherapy	156	0.74	0.34–1.60	0.448	223	1.19	0.69–2.03	0.539
Non-chemotherapy	549	1.13	0.79–1.60	0.502	1873	1.22	1.03–1.44	0.019
PRDX2								
Adjuvant chemotherapy	163	2.02	1.09–3.73	0.023	594	1.33	0.98–1.80	0.064
Neoadjuvant chemotherapy	156	1.41	0.66–3.02	0.375	223	1.24	0.72–2.16	0.438
Non-chemotherapy	549	1.14	0.80–1.62	0.483	1873	1.07	0.90–1.26	0.444
PRDX3								
Adjuvant chemotherapy	163	2.03	1.10–3.73	0.021	594	0.80	0.59–1.08	0.148
Neoadjuvant chemotherapy	156	1.05	0.49–2.23	0.906	223	0.95	0.55–1.65	0.851
Non-chemotherapy	549	0.79	0.56–1.12	0.185	1873	0.84	0.71–1.00	0.043
PRDX4								
Adjuvant chemotherapy	163	1.97	1.07–3.65	0.027	594	1.02	0.75–1.38	0.906
Neoadjuvant chemotherapy	156	0.68	0.31–1.48	0.325	223	1.19	0.69–2.07	0.529
Non-chemotherapy	549	1.28	0.90–1.82	0.177	1873	1.37	1.16–1.62	0.000
PRDX5								
Adjuvant chemotherapy	0	/	/	/	255	0.50	0.30–0.81	0.005
Neoadjuvant chemotherapy	107	0.67	0.24–1.89	0.446	111	1.22	0.58–2.57	0.595
Non-chemotherapy	0	/	/	/	243	0.66	0.38–1.14	0.131
PRDX6								
Adjuvant chemotherapy	163	0.86	0.48–1.56	0.625	594	1.10	0.81–1.49	0.532
Neoadjuvant chemotherapy	156	0.72	0.33–1.55	0.395	223	1.09	0.63–1.88	0.769
Non-chemotherapy	549	1.33	0.94–1.88	0.110	1873	1.19	1.00–1.40	0.044